Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCANTO trial of nasal cartilage implantation for patellofemoral osteoarthritis
NL-OMON59099Phase 2Not yet recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rimegepant in Patellofemoral Arthritis (3 arms), sponsored by University Hospital Basel. Primary endpoint: Change in KOOS-5 subjective score from baseline to 24 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
Patellofemoral Arthritis
Beyond the preview
Go deeper on NL-OMON59099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59099.